📊 TXMD Key Takeaways
Is TherapeuticsMD, Inc. (TXMD) a Good Investment?
TherapeuticsMD exhibits severe financial distress with long-term debt (93.6M) nearly 2.5x total assets (37.6M), creating imminent solvency risk. Negative operating cash flow (-8.7M), deeply negative operating margins (-99.9%), and inability to service debt (interest coverage: -90.4x) indicate the company cannot sustain operations or meet obligations. Minimal revenue base (724K) with unsustainable cost structure provides no clear path to profitability.
Why Buy TherapeuticsMD, Inc. Stock? TXMD Key Strengths
- Revenue growth of 35.3% YoY demonstrates demand for products despite financial distress
- Current ratio of 3.11x and quick ratio of 1.74x provide near-term liquidity cushion
- Cash position of 8.4M offers runway for operational adjustments or restructuring negotiations
TXMD Stock Risks: TherapeuticsMD, Inc. Investment Risks
- Long-term debt (93.6M) exceeds total assets (37.6M), indicating insolvency and default risk
- Negative operating cash flow (-8.7M) and free cash flow (-8.7M) show unsustainable cash burn
- Inability to cover interest expenses with negative interest coverage ratio (-90.4x) suggests debt servicing failure is imminent
- Tiny absolute revenue (724K) provides insufficient cash generation to support debt burden
- Suspicious accounting (179.8% gross margin, positive net income amid negative operating income) raises quality-of-earnings concerns
Key Metrics to Watch
- Operating cash flow trend and timeline to positive cash generation
- Debt refinancing status and negotiations with creditors regarding 93.6M long-term debt
- Revenue growth sustainability and path to operating profitability
TherapeuticsMD, Inc. (TXMD) Financial Metrics & Key Ratios
💡 AI Analyst Insight
Strong liquidity with a 3.11x current ratio provides a solid financial cushion.
TXMD Profit Margin, ROE & Profitability Analysis
TXMD vs Healthcare Sector: How TherapeuticsMD, Inc. Compares
How TherapeuticsMD, Inc. compares to Healthcare sector averages
Sector benchmarks are approximate industry averages. Actual sector performance may vary.
Is TherapeuticsMD, Inc. Stock Overvalued? TXMD Valuation Analysis 2026
Based on fundamental analysis, TherapeuticsMD, Inc. shows some fundamental concerns relative to the Healthcare sector in 2026.
Note: This is a fundamental analysis based on SEC filings. For P/E ratio, price targets, and market-based valuation, consult financial data providers. This is not investment advice.
TherapeuticsMD, Inc. Balance Sheet: TXMD Debt, Cash & Liquidity
TXMD Revenue & Earnings Growth: 5-Year Financial Trend
5-Year Trend Summary: TherapeuticsMD, Inc.'s revenue has grown significantly by 261% over the 5-year period, indicating strong business expansion. The most recent EPS of $-0.19 indicates the company is currently unprofitable.
TXMD Revenue Growth, EPS Growth & YoY Performance
TXMD Quarterly Earnings & Performance
| Quarter | Revenue | Net Income | EPS |
|---|---|---|---|
| Q1 2026 | $393.0K | $95.0K | $0.01 |
| Q3 2025 | $547.0K | $50.0K | $0.00 |
| Q2 2025 | $234.0K | -$102.0K | $-0.01 |
| Q1 2025 | $313.0K | -$653.0K | $-0.06 |
| Q3 2023 | -$53.0K | -$2.4M | $-0.32 |
| Q2 2023 | $348.0K | -$2.4M | $-0.24 |
| Q1 2023 | $416.0K | -$3.6M | $-0.37 |
| Q3 2022 | $20.9M | -$29.0M | $-3.13 |
Data sourced from SEC EDGAR 10-Q quarterly filings. Figures may represent quarterly or cumulative values.
TherapeuticsMD, Inc. Dividends, Buybacks & Capital Allocation
TXMD SEC Filings: Latest 10-K & 10-Q Analysis
Access official SEC EDGAR filings for TherapeuticsMD, Inc. (CIK: 0000025743)
📋 Recent SEC Filings
❓ Frequently Asked Questions about TXMD
What is the AI rating for TXMD?
TherapeuticsMD, Inc. (TXMD) has an AI rating of STRONG SELL with 88% confidence, based on fundamental analysis of SEC EDGAR filings.
What are TXMD's key strengths?
Claude: Revenue growth of 35.3% YoY demonstrates demand for products despite financial distress. Current ratio of 3.11x and quick ratio of 1.74x provide near-term liquidity cushion.
What are the risks of investing in TXMD?
Claude: Long-term debt (93.6M) exceeds total assets (37.6M), indicating insolvency and default risk. Negative operating cash flow (-8.7M) and free cash flow (-8.7M) show unsustainable cash burn.
What is TXMD's revenue and growth?
TherapeuticsMD, Inc. reported revenue of $724.0K.
Does TXMD pay dividends?
TherapeuticsMD, Inc. does not currently pay dividends.
Where can I find TXMD SEC filings?
Official SEC filings for TherapeuticsMD, Inc. (CIK: 0000025743) including 10-K, 10-Q, and 8-K reports are available on SEC EDGAR.
What is TXMD's EPS?
TherapeuticsMD, Inc. has a diluted EPS of $0.01.
How is the AI analysis conducted?
Two independent AI systems — Claude (Anthropic) and ChatGPT (OpenAI) — analyze SEC EDGAR filings including 10-K annual reports and 10-Q quarterly reports. Each AI evaluates financial health, profitability ratios, balance sheet strength, and growth metrics. The combined rating reflects both perspectives for balanced insights.
Is TXMD a good stock to buy right now?
Based on our AI fundamental analysis in May 2026, TherapeuticsMD, Inc. has a STRONG SELL rating with 88% confidence. Review the strengths and risks sections above before making a decision. This is not investment advice.
Is TXMD stock overvalued or undervalued?
Valuation metrics for TXMD: ROE of 0.4% (sector avg: 15%), net margin of 13.1% (sector avg: 12%). Compare these metrics with sector averages to assess valuation.
Should I buy TXMD stock in 2026?
Our dual AI analysis gives TherapeuticsMD, Inc. a combined STRONG SELL rating for 2026. Revenue is data pending, with profitability above sector average. Always conduct your own research.
What is TXMD's free cash flow?
TherapeuticsMD, Inc.'s operating cash flow is $-8.7M, with capital expenditures of $21.0K. FCF margin is -1,204.7%.
How does TXMD compare to other Healthcare stocks?
Vs Healthcare sector averages: Net margin 13.1% (avg: 12%), ROE 0.4% (avg: 15%), current ratio 3.11 (avg: 2).
Is TherapeuticsMD, Inc. carrying too much debt?
TXMD has a debt-to-equity ratio of 3.47x, which is above the Healthcare sector average of 0.6x. However, the current ratio of 3.11 suggests adequate short-term liquidity.